Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)

Leviatan S and Segal E: Identifying gut microbes that affect human health. Nature. 587:373–374. 2020. View Article : Google Scholar

Greenhalgh K, Meyer KM, Aagaard KM and Wilmes P: The human gut microbiome in health: Establishment and resilience of microbiota over a lifetime. Environ Microbiol. 18:2103–2116. 2016. View Article : Google Scholar

Feng Q, Chen WD and Wang YD: Gut microbiota: An integral moderator in health and disease. Front Microbiol. 9:1512018. View Article : Google Scholar

Vaishnava S, Behrendt CL, Ismail AS, Eckmann L and Hooper LV: Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA. 105:20858–20863. 2008. View Article : Google Scholar

Belkaid Y and Naik S: Compartmentalized and systemic control of tissue immunity by commensals. Nat Immunol. 14:646–653. 2013. View Article : Google Scholar

Magnúsdóttir S, Ravcheev D, de Crécy-Lagard V and Thiele I: Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. Front Genet. 6:1482015. View Article : Google Scholar

Zheng D, Liwinski T and Elinav E: Interaction between microbiota and immunity in health and disease. Cell Res. 30:492–506. 2020. View Article : Google Scholar

Sharma VR, Singh M, Kumar V, Yadav M, Sehrawat N, Sharma DK and Sharma AK: Microbiome dysbiosis in cancer: Exploring therapeutic strategies to counter the disease. Semin Cancer Biol. 70:61–70. 2021. View Article : Google Scholar

Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA and Knight R: The microbiome and human cancer. Science. 371:eabc45522021. View Article : Google Scholar

The integrative human microbiome project. Nature. 569:641–648. 2019. View Article : Google Scholar

Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, Costea PI, Godneva A, Kalka IN, Bar N, et al: Environment dominates over host genetics in shaping human gut microbiota. Nature. 555:210–215. 2018. View Article : Google Scholar

Korem T, Zeevi D, Suez J, Weinberger A, Avnit-Sagi T, Pompan-Lotan M, Matot E, Jona G, Harmelin A, Cohen N, et al: Growth dynamics of gut microbiota in health and disease inferred from single metagenomic samples. Science. 349:1101–1106. 2015. View Article : Google Scholar

Whon TW, Shin NR, Kim JY and Roh SW: Omics in gut microbiome analysis. J Microbiol. 59:292–297. 2021. View Article : Google Scholar

Geva-Zatorsky N, Sefik E, Kua L, Pasman L, Tan TG, Ortiz-Lopez A, Yanortsang TB, Yang L, Jupp R, Mathis D, et al: Mining the human gut microbiota for immunomodulatory organisms. Cell. 168:928–943.e11. 2017. View Article : Google Scholar

Haber AL, Biton M, Rogel N, Herbst RH, Shekhar K, Smillie C, Burgin G, Delorey TM, Howitt MR, Katz Y, et al: A single-cell survey of the small intestinal epithelium. Nature. 551:333–339. 2017. View Article : Google Scholar

Almeida A, Nayfach S, Boland M, Strozzi F, Beracochea M, Shi ZJ, Pollard KS, Sakharova E, Parks DH, Hugenholtz P, et al: A unified catalog of 204,938 reference genomes from the human gut microbiome. Nat Biotechnol. 39:105–114. 2021. View Article : Google Scholar

Vujkovic-Cvijin I, Sklar J, Jiang L, Natarajan L, Knight R and Belkaid Y: Host variables confound gut microbiota studies of human disease. Nature. 587:448–454. 2020. View Article : Google Scholar

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar

Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N and Miller WH Jr: A review of cancer immunotherapy: From the past, to the present, to the future. Curr Oncol. 27(Suppl 2): S87–S97. 2020. View Article : Google Scholar

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T and Zare P: Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 18:592020. View Article : Google Scholar

Robert C: A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 11:38012020. View Article : Google Scholar

Fridman WH, Zitvogel L, Sautès-Fridman C and Kroemer G: The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 14:717–734. 2017. View Article : Google Scholar

Hiam-Galvez KJ, Allen BM and Spitzer MH: Systemic immunity in cancer. Nat Rev Cancer. 21:345–359. 2021. View Article : Google Scholar

Ledford H, Else H and Warren M: Cancer immunologists scoop medicine nobel prize. Nature. 562:20–21. 2018. View Article : Google Scholar

Shin EC: Cancer immunotherapy: Special issue of BMB Reports in 2021. BMB Rep. 54:12021. View Article : Google Scholar

Chen DS and Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013. View Article : Google Scholar

Huang PW and Chang JWC: Immune checkpoint inhibitors win the 2018 nobel prize. Biomed J. 42:299–306. 2019. View Article : Google Scholar

Waldman AD, Fritz JM and Lenardo MJ: A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat Rev Immunol. 20:651–668. 2020. View Article : Google Scholar

Shen CR and Chen YS: Immune checkpoint blockade therapy: The 2014 tang prize in biopharmaceutical science. Biomed J. 38:5–8. 2015. View Article : Google Scholar

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar

Long J, Qi Z and Rongxin Z: PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. Cancer Biol Med. 15:116–123. 2018. View Article : Google Scholar

Seidel JA, Otsuka A and Kabashima K: Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Front Oncol. 8:862018. View Article : Google Scholar

Wei SC, Duffy CR and Allison JP: Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8:1069–1086. 2018. View Article : Google Scholar

Twomey JD and Zhang B: Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 23:392021. View Article : Google Scholar

Xin Yu J, Hubbard-Lucey VM and Tang J: Immuno-oncology drug development goes global. Nat Rev Drug Discov. 18:899–900. 2019. View Article : Google Scholar

Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol. 8:5612017. View Article : Google Scholar

Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, et al: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 377:1824–1835. 2017. View Article : Google Scholar

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al: Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 378:1789–1801. 2018. View Article : Google Scholar

Kennedy LB and Salama AKS: A review of cancer immunotherapy toxicity. CA Cancer J Clin. 70:86–104. 2020. View Article : Google Scholar

Barrueto L, Caminero F, Cash L, Makris C, Lamichhane P and Deshmukh RR: Resistance to checkpoint inhibition in cancer immunotherapy. Transl Oncol. 13:1007382020. View Article : Google Scholar

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, et al: Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6:827–837. 2016. View Article : Google Scholar

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B and Johnson DB: Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 391:9332018. View Article : Google Scholar

Teixidor E and Bosch-Barrera J: The dark side of immunotherapy: Challenges facing the new hope in cancer treatment. Ann Transl Med. 7(Suppl 6): S1832019. View Article : Google Scholar

Havel JJ, Chowell D and Chan TA: The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 19:133–150. 2019. View Article : Google Scholar

Pezo RC, Wong M and Martin A: Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities. Therap Adv Gastroenterol. 12:17562848198709112019. View Article : Google Scholar

Chang AE, Golob JL, Schmidt TM, Peltier DC, Lao CD and Tewari M: Targeting the gut microbiome to mitigate immunotherapy-induced colitis in cancer. Trends Cancer. 7:583–593. 2021. View Article : Google Scholar

Sarshar M, Scribano D, Ambrosi C, Palamara AT and Masotti A: Fecal microRNAs as innovative biomarkers of intestinal diseases and effective players in host-microbiome interactions. Cancers (Basel). 12:21742020. View Article : Google Scholar

Murciano-Goroff YR, Warner AB and Wolchok JD: The future of cancer immunotherapy: Microenvironment-targeting combinations. Cell Res. 30:507–519. 2020. View Article : Google Scholar

Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, Torino F, Banna GL, Tonini G and Libra M: Gut microbiota and cancer: From pathogenesis to therapy. Cancers (Basel). 11:382019. View Article : Google Scholar

Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, et al: Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 371:595–602. 2021. View Article : Google Scholar

Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, et al: Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 371:602–609. 2021. View Article : Google Scholar

Maynard CL, Elson CO, Hatton RD and Weaver CT: Reciprocal interactions of the intestinal microbiota and immune system. Nature. 489:231–241. 2012. View Article : Google Scholar

Belkaid Y and Hand TW: Role of the microbiota in immunity and Inflammation. Cell. 157:121–141. 2014. View Article : Google Scholar

Jain T, Sharma P, Are AC, Vickers SM and Dudeja V: New insights into the cancer-microbiome-immune axis: Decrypting a decade of discoveries. Front Immunol. 12:6220642021. View Article : Google Scholar

Koenig JE, Spor A, Scalfone N, Fricker AD, Stombaugh J, Knight R, Angenent LT and Ley RE: Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci USA. 108(Suppl 1): S4578–S4585. 2011. View Article : Google Scholar

Gomez de Agüero M, Ganal-Vonarburg SC, Fuhrer T, Rupp S, Uchimura Y, Li H, Steinert A, Heikenwalder M, Hapfelmeier S, Sauer U, et al: The maternal microbiota drives early postnatal innate immune development. Science. 351:1296–1302. 2016. View Article : Google Scholar

Russell SL, Gold MJ, Hartmann M, Willing BP, Thorson L, Wlodarska M, Gill N, Blanchet MR, Mohn WW, McNagny KM and Finlay BB: Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO Rep. 13:440–447. 2012. View Article : Google Scholar

Cahenzli J, Köller Y, Wyss M, Geuking MB and McCoy KD: Intestinal microbial diversity during early-life colonization shapes long-term IgE levels. Cell Host Microbe. 14:559–570. 2013. View Article : Google Scholar

Ge Y, Wang X, Guo Y, Yan J, Abuduwaili A, Aximujiang K, Yan J and Wu M: Gut microbiota influence tumor development and alter interactions with the human immune system. J Exp Clin Cancer Res. 40:422021. View Article : Google Scholar

Shi N, Li N, Duan X and Niu H: Interaction between the gut microbiome and mucosal immune system. Mil Med Res. 4:142017.

Lazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, Picu A, Petcu L and Chifiriuc MC: Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 9:18302018. View Article : Google Scholar

Shan M, Gentile M, Yeiser JR, Walland AC, Bornstein VU, Chen K, He B, Cassis L, Bigas A, Cols M, et al: Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science. 342:447–453. 2013. View Article : Google Scholar

Macpherson AJ and Uhr T: Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 303:1662–1665. 2004. View Article : Google Scholar

Bevins CL and Salzman NH: Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol. 9:356–368. 2011. View Article : Google Scholar

Chu H and Mazmanian SK: Innate immune recognition of the microbiota promotes host-microbial symbiosis. Nat Immunol. 14:668–675. 2013. View Article : Google Scholar

Vance RE, Isberg RR and Portnoy DA: Patterns of pathogenesis: Discrimination of pathogenic and nonpathogenic microbes by the innate immune system. Cell Host Microbe. 6:10–21. 2009. View Article : Google Scholar

Mogensen TH: Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 22:240–273. 2009. View Article : Google Scholar

Suresh R and Mosser DM: Pattern recognition receptors in innate immunity, host defense, and immunopathology. Adv Physiol Educ. 37:284–291. 2013. View Article : Google Scholar

Gaudet RG, Guo CX, Molinaro R, Kottwitz H, Rohde JR, Dangeard AS, Arrieumerlou C, Girardin SE and Gray-Owen SD: Innate recognition of intracellular bacterial growth is driven by the TIFA-dependent cytosolic surveillance pathway. Cell Rep. 19:1418–1430. 2017. View Article : Google Scholar

Bai L, Li W, Zheng W, Xu D, Chen N and Cui J: Promising targets based on pattern recognition receptors for cancer immunotherapy. Pharmacol Res. 159:1050172020. View Article : Google Scholar

Luis Muñoz-Carrillo J, Francisco Contreras-Cordero J, Gutiérrez-Coronado O, Trinidad Villalobos-Gutiérrez P, Guillermo Ramos-Gracia L and Elizabeth Hernández-Reyes V: Cytokine profiling plays a crucial role in activating immune system to clear infectious pathogens. Immune Response Activation and Immunomodulation. IntechOpen; 2019, View Article : Google Scholar

Kim M and Kim CH: Regulation of humoral immunity by gut microbial products. Gut Microbes. 8:392–399. 2017. View Article : Google Scholar

Nagashima K, Sawa S, Nitta T, Tsutsumi M, Okamura T, Penninger JM, Nakashima T and Takayanagi H: Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nat Immunol. 18:675–682. 2017. View Article : Google Scholar

Cong Y, Feng T, Fujihashi K, Schoeb TR and Elson CO: A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci USA. 106:19256–19261. 2009. View Article : Google Scholar

Tezuka H and Ohteki T: Regulation of IgA production by intestinal dendritic cells and related cells. Front Immunol. 10:18912019. View Article : Google Scholar

Wu HJ and Wu E: The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 3:4–14. 2012. View Article : Google Scholar

Lee GR: The Balance of Th17 versus Treg cells in autoimmunity. Int J Mol Sci. 19:7302018. View Article : Google Scholar

Mazmanian SK, Liu CH, Tzianabos AO and Kasper DL: An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 122:107–118. 2005. View Article : Google Scholar

Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, Mulder I, Lan A, Bridonneau C, Rochet V, Pisi A, De Paepe M, Brandi G, et al: The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 31:677–689. 2009. View Article : Google Scholar

Valeri M and Raffatellu M: Cytokines IL-17 and IL-22 in the host response to infection. Pathog Dis. 74:ftw1112016. View Article : Google Scholar

Liu R, Lauridsen HM, Amezquita RA, Pierce RW, Jane-Wit D, Fang C, Pellowe AS, Kirkiles-Smith NC, Gonzalez AL and Pober JS: IL-17 promotes neutrophil-mediated immunity by activating microvascular pericytes and not endothelium. J Immunol. 197:2400–2408. 2016. View Article : Google Scholar

Stary G, Olive A, Radovic-Moreno AF, Gondek D, Alvarez D, Basto PA, Perro M, Vrbanac VD, Tager AM, Shi J, et al: VACCINES. A mucosal vaccine against chlamydia trachomatis generates two waves of protective memory T cells. Science. 348:aaa82052015. View Article : Google Scholar

Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wilhelm C, Tolaini M, Menzel U, et al: Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol. 12:255–263. 2011. View Article : Google Scholar

Oh JZ, Ravindran R, Chassaing B, Carvalho FA, Maddur MS, Bower M, Hakimpour P, Gill KP, Nakaya HI, Yarovinsky F, et al: TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity. 41:478–492. 2014. View Article : Google Scholar

Sandrini S, Aldriwesh M, Alruways M and Freestone P: Microbial endocrinology: Host-bacteria communication within the gut microbiome. J Endocrinol. 225:R21–R34. 2015. View Article : Google Scholar

Gensollen T, Iyer SS, Kasper DL and Blumberg RS: How colonization by microbiota in early life shapes the immune system. Science. 352:539–544. 2016. View Article : Google Scholar

Schmidt TSB, Raes J and Bork P: The human gut microbiome: From association to modulation. Cell. 172:1198–1215. 2018. View Article : Google Scholar

Bultman SJ: Emerging roles of the microbiome in cancer. Carcinogenesis. 35:249–255. 2014. View Article : Google Scholar

Cani PD: Human gut microbiome: Hopes, threats and promises. Gut. 67:1716–1725. 2018. View Article : Google Scholar

LeBlanc JG, Chain F, Martín R, Bermúdez-Humarán LG, Courau S and Langella P: Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb Cell Fact. 16:792017. View Article : Google Scholar

Nakkarach A, Foo HL, Song AA, Mutalib NEA, Nitisinprasert S and Withayagiat U: Anti-cancer and anti-inflammatory effects elicited by short chain fatty acids produced by Escherichia coli isolated from healthy human gut microbiota. Microb Cell Fact. 20:362021. View Article : Google Scholar

Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF and Dinan TG: Minireview: Gut microbiota: The neglected endocrine organ. Mol Endocrinol. 28:1221–1238. 2014. View Article : Google Scholar

Pabst O: New concepts in the generation and functions of IgA. Nat Rev Immunol. 12:821–832. 2012. View Article : Google Scholar

Mantis NJ, Rol N and Corthésy B: Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol. 4:603–611. 2011. View Article : Google Scholar

Mathias A, Pais B, Favre L, Benyacoub J and Corthésy B: Role of secretory IgA in the mucosal sensing of commensal bacteria. Gut Microbes. 5:688–695. 2014. View Article : Google Scholar

Levy M, Kolodziejczyk AA, Thaiss CA and Elinav E: Dysbiosis and the immune system. Nat Rev Immunol. 17:219–232. 2017. View Article : Google Scholar

Round JL and Mazmanian SK: Inducible Foxp3⁺ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA. 107:12204–12209. 2010. View Article : Google Scholar

Cianci R, Franza L, Schinzari G, Rossi E, Ianiro G, Tortora G, Gasbarrini A, Gambassi G and Cammarota G: The interplay between immunity and microbiota at intestinal immunological niche: The case of cancer. Int J Mol Sci. 20:5012019. View Article : Google Scholar

Shui L, Yang X, Li J, Yi C, Sun Q and Zhu H: Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy. Front Immunol. 10:29892020. View Article : Google Scholar

Zipkin M: Fecal microbiota potentiate checkpoint inhibitors, unleash microbiome startups. Nat Biotechnol. 39:529–532. 2021. View Article : Google Scholar

Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar

Niedzwiecki MM, Walker DI, Vermeulen R, Chadeau-Hyam M, Jones DP and Miller GW: The exposome: Molecules to populations. Annu Rev Pharmacol Toxicol. 59:107–127. 2019. View Article : Google Scholar

Arem H and Loftfield E: Cancer epidemiology: A survey of modifiable risk factors for prevention and survivorship. Am J Lifestyle Med. 12:200–210. 2017. View Article : Google Scholar

IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 100:1–441. 2012.

Wroblewski LE, Peek RM Jr and Wilson KT: Helicobacter pylori and gastric cancer: Factors that modulate disease risk. Clin Microbiol Rev. 23:713–739. 2010. View Article : Google Scholar

Whisner CM and Athena Aktipis C: The role of the microbiome in cancer initiation and progression: How microbes and cancer cells utilize excess energy and promote one another's growth. Curr Nutr Rep. 8:42–51. 2019. View Article : Google Scholar

Villéger R, Lopès A, Carrier G, Veziant J, Billard E, Barnich N, Gagnière J, Vazeille E and Bonnet M: Intestinal microbiota: A novel target to improve anti-tumor treatment? Int J Mol Sci. 20:45842019. View Article : Google Scholar

Li W, Deng X and Chen T: Exploring the modulatory effects of gut microbiota in anti-cancer therapy. Front Oncol. 11:6444542021. View Article : Google Scholar

Guerra L, Cortes-Bratti X, Guidi R and Frisan T: The biology of the cytolethal distending toxins. Toxins (Basel). 3:172–190. 2011. View Article : Google Scholar

Sun J, Hobert ME, Duan Y, Rao AS, He TC, Chang EB and Madara JL: Crosstalk between NF-kappaB and beta-catenin pathways in bacterial-colonized intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 289:G129–G137. 2005. View Article : Google Scholar

Liu X, Lu R, Wu S and Sun J: Salmonella regulation of intestinal stem cells through the Wnt/beta-catenin pathway. FEBS Lett. 584:911–916. 2010. View Article : Google Scholar

Scanu T, Spaapen RM, Bakker JM, Pratap CB, Wu LE, Hofland I, Broeks A, Shukla VK, Kumar M, Janssen H, et al: Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma. Cell Host Microbe. 17:763–774. 2015. View Article : Google Scholar

Li Y, Tinoco R, Elmé L, Segota I, Xian Y, Fujita Y, Sahu A, Zarecki R, Marie K, Feng Y, et al: Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5^−/− mice. Nat Commun. 10:14922019. View Article : Google Scholar

Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, Narushima S, Vlamakis H, Motoo I, Sugita K, et al: A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 565:600–605. 2019. View Article : Google Scholar

Valguarnera E and Wardenburg JB: Good gone bad: One toxin away from disease for Bacteroides fragilis. J Mol Biol. 432:765–785. 2020. View Article : Google Scholar

Thiele Orberg E, Fan H, Tam AJ, Dejea CM, Destefano Shields CE, Wu S, Chung L, Finard BB, Wu X, Fathi P, et al: The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol. 10:421–433. 2017. View Article : Google Scholar

Geis AL, Fan H, Wu X, Wu S, Huso DL, Wolfe JL, Sears CL, Pardoll DM and Housseau F: Regulatory T-cell response to enterotoxigenic Bacteroides fragilis colonization triggers IL17-dependent colon carcinogenesis. Cancer Discov. 5:1098–1109. 2015. View Article : Google Scholar

Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, et al: Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 14:207–215. 2013. View Article : Google Scholar

Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, et al: Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350:1084–1089. 2015. View Article : Google Scholar

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al: Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 359:91–97. 2018. View Article : Google Scholar

Sharifi-Rad J, Rodrigues CF, Stojanović-Radić Z, Dimitrijević M, Aleksić A, Neffe-Skocińska K, Zielińska D, Kołożyn-Krajewska D, Salehi B, Milton Prabu S, et al: Probiotics: Versatile bioactive components in promoting human health. Medicina (Kaunas). 56:4332020. View Article : Google Scholar

Banna GL, Torino F, Marletta F, Santagati M, Salemi R, Cannarozzo E, Falzone L, Ferraù F and Libra M: Lactobacillus rhamnosus GG: An overview to explore the rationale of its use in cancer. Front Pharmacol. 8:6032017. View Article : Google Scholar

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, et al: Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 350:1079–1084. 2015. View Article : Google Scholar

Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, et al: Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 7:103912016. View Article : Google Scholar

Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP and Koh AY: Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 19:848–855. 2017. View Article : Google Scholar

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, et al: Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 28:1368–1379. 2017. View Article : Google Scholar

Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ and Gajewski TF: The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 359:104–108. 2018. View Article : Google Scholar

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 359:97–103. 2018. View Article : Google Scholar

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, et al: Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 29:1437–1444. 2018. View Article : Google Scholar

Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, Zheng H, Yao C, Wang Y and Lu S: The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in chinese patients with NSCLC. J Thorac Oncol. 14:1378–1389. 2019. View Article : Google Scholar

Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, Jiang W, Cai S, Zhao P, Song R, et al: Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 7:1932019. View Article : Google Scholar

Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, Folkerts M, Reining L, Trent J, Highlander SK and Pal SK: Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. Eur Urol. 78:498–502. 2020. View Article : Google Scholar

Xu X, Lv J, Guo F, Li J, Jia Y, Jiang D, Wang N, Zhang C, Kong L, Liu Y, et al: Gut Microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-type colorectal cancer via metabolic pathway. Front Microbiol. 11:8142020. View Article : Google Scholar

Mager LF, Burkhard R, Pett N, Cooke NCA, Brown K, Ramay H, Paik S, Stagg J, Groves RA, Gallo M, et al: Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 369:1481–1489. 2020. View Article : Google Scholar

Si W, Liang H, Bugno J, Xu Q, Ding X, Yang K, Fu Y, Weichselbaum RR, Zhao X and Wang L: Lactobacillus rhamnosus GG induces cGAS/STING-dependent type I interferon and improves response to immune checkpoint blockade. Gut. gutjnl-2020-323426. 2021.Epub ahead of print. View Article : Google Scholar

Shi Y, Zheng W, Yang K, Harris KG, Ni K, Xue L, Lin W, Chang EB, Weichselbaum RR and Fu YX: Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med. 217:e201922822020. View Article : Google Scholar

Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, Ganju V, Polikoff J, Saad F, Humanski P, et al: Randomized, double-blind, phase III Trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 35:40–47. 2017. View Article : Google Scholar

Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al: The genomic complexity of primary human prostate cancer. Nature. 470:214–220. 2011. View Article : Google Scholar

Nicholson LT and Fong L: Immune checkpoint inhibition in prostate cancer. Trends Cancer. 6:174–177. 2020. View Article : Google Scholar

Venkatachalam S, McFarland TR, Agarwal N and Swami U: Immune checkpoint inhibitors in prostate cancer. Cancers (Basel). 13. pp. 21872021, View Article : Google Scholar

Crocetto F, Boccellino M, Barone B, Di Zazzo E, Sciarra A, Galasso G, Settembre G, Quagliuolo L, Imbimbo C, Boffo S, et al: The crosstalk between prostate cancer and microbiota inflammation: Nutraceutical products are useful to balance this interplay? Nutrients. 12:26482020. View Article : Google Scholar

Ferro M, Lucarelli G, Crocetto F, Dolce P, Verde A, La Civita E, Zappavigna S, de Cobelli O, Di Lorenzo G, Facchini BA, et al: First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. Crit Rev Oncol Hematol. 157:1031982021. View Article : Google Scholar

Barbosa AM, Gomes-Gonçalves A, Castro AG and Torrado E: Immune system efficiency in cancer and the microbiota influence. Pathobiology. 88:170–186. 2021. View Article : Google Scholar

Chen D, Wu J, Jin D, Wang B and Cao H: Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 145:2021–2031. 2019. View Article : Google Scholar

Thompson S, Guetterman H, Taylor A, Bogner A, Martin D, Farrell JJ, Swanson KS and Holscher H: Dietary predictors of fecal microbiota transplantation success. J Acad Nutr Diet. 116(Suppl 9): A762016. View Article : Google Scholar

Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, et al: Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: Phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 7:e660–e670. 2020. View Article : Google Scholar

Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, Oosting SF, Schröder CP, Hiltermann TJN, van der Wekken AJ, et al: ⁸⁹Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 24:1852–1858. 2018. View Article : Google Scholar

Kyte JA, Røssevold A, Falk RS and Naume B: ALICE: A randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer. J Transl Med. 18:2522020. View Article : Google Scholar

Cohen R, Pudlarz T, Garcia-Larnicol ML, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, et al: Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment. Bull Cancer. 107:438–446. 2020.In French. View Article : Google Scholar